---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Clinical presentation - signs and symptoms. Topics: Mood symptoms: depressed mood and loss of interest or pleasure; Mood symptoms: anhedonia; Symptom clusters: mood, insomnia, somatic, and anxiety symptoms in TRD; Somatic and neurovegetative symptoms: fatigue, insomnia, and pain before TRD onset; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Mood symptoms: depressed mood and loss of interest or pleasure

> “NSDUH respondents were classified as having had a major depressive episode (MDE) in the past 12 months if (1) they had at least one period of 2 weeks or longer in the past year when, for most of the day nearly every day, they felt depressed or lost interest or pleasure in daily activities; and (2) they also had problems with sleeping, eating, energy, concentration, self‐worth, or having recurrent thoughts of death or recurrent suicidal ideation.”

Source: [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm)

<a id="topic-2.2.1.6-2"></a>

### Mood symptoms: anhedonia

> “Anhedonia is a core component of depression endorsed by 35‐75% of patients, and may be a risk factor for TRD in persons whose treatment history is delimited to SSRIs”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-3"></a>

### Symptom clusters: mood, insomnia, somatic, and anxiety symptoms in TRD

> “This work found that patients with TRD referred for rTMS experience four distinct symptom clusters - mood, insomnia, somatic and anxiety symptoms - and that these clusters respond differently to rTMS.”

Source: [Kaster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722479/)

<a id="topic-2.2.1.6-4"></a>

### Somatic and neurovegetative symptoms: fatigue, insomnia, and pain before TRD onset

> “Ten percent of subjects newly diagnosed and treated for depression developed TRD within a year. They were younger and suffered more frequently from fatigue, substance use disorders, anxiety, psychiatric conditions, insomnia, and pain than non‐TRD patients.”

Source: [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)

<a id="topic-2.2.1.6-5"></a>

### Cognitive symptoms: deficits in multiple cognitive domains

> “Cognitive dysfunction is considered a core feature in the psychopathology of MDD during both the acute phase and the residual period and represents one of the symptoms for which a clinical need has been identified. Sufficient evidence exists indicating that patients suffering from MDD exhibit deficits in multiple domains of cognitive function, including learning and memory (verbal and nonverbal), attention, psychomotor speed, executive function, emotional processing and social cognition. Cognitive dysfunction may persist as residual symptom, despite resolution of the depressive symptoms in the acute phase.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “Cognitive deficits in MDD are prevalent, persistent, and often progressively increase as a function of illness severity and duration; they are associated with attenuated response to select antidepressants, and may represent a risk factor for TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-6"></a>

### Anxiety symptoms: anxious depression and comorbid anxiety disorders

> “Anxiety symptoms are frequently reported in TRD populations, and their presence in MDD is associated with a more severe illness presentation, lower probability of remission, comorbidities and suicidality”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

> “At baseline, anxiety disorders were present in 53.92%, 44.11%, and 21.72% of patients with TRD, MDD+SI/SA, and MDD alone, respectively.”

Source: [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/)

> “Two hundred fifty-three patients, who had at least one post-baseline Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale score were included in the analysis. Of them, 182 subjects presented anxious and 71 nonanxious depression.”

Source: [Chaikali et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42127355/)

> “The anxiety symptom cluster was significantly less responsive to treatment than other symptom clusters (t(6001) = -8.02, p < 0.001).”

Source: [Kaster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722479/)

<a id="topic-2.2.1.6-7"></a>

### Psychotic and mixed features

> “Mixed features are reported to be present in approximately 25% of persons with MDD and are associated with attenuated antidepressant response, although it remains to be determined whether they are a risk factor specifically for TRD”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.6-8"></a>

### Suicidal ideation and hopelessness

> “More than half of patients reported thoughts or wishes of death to self and significant hopelessness.”
> “Patients with TRD are more likely than not to report prominent suicidal ideation and hopelessness.”

Source: [Papakostas et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12891091/)

<a id="topic-2.2.1.6-9"></a>

### Functional impairment: work, social functioning, and quality of life

> “During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.6-10"></a>

### Residual symptoms after treatment

> “Nearly 70% of patients with MDD experience residual symptoms with first line standard of care. These may include anxiety, impaired cognition, fatigue and sleep disturbance.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

> “This was highlighted in the STAR*D trial, in which it was observed that only 10% of persons “in remission” were fully asymptomatic”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
